SCHEMBL1689405

SCHEMBL1689405

NC(=O)C(C(=O)Nc1ccccc1)c1ccc(C(=O)Nc2nn(-c3cccc(Cl)c3)cc2N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC3 O15379 1/20 0.48
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.40
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
PARP3 Q9Y6F1 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BRAF P15056 1/20 0.39
LMNA P02545 2/20 0.39
AURKA O14965 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689347 0.92 HDAC1 (0.55) HDAC1HDAC2HDAC3RAB9APARP1
SCHEMBL1754072 0.88 HDAC1 (0.60) HDAC1HDAC2HDAC3RAB9ALMNA
SCHEMBL2438059 0.81 HDAC1 (0.54) HDAC1HDAC2HDAC3MEN1KMT2A
SCHEMBL13950308 0.80 HDAC1 (0.47) HDAC1HDAC2HDAC3MEN1KMT2A
SCHEMBL1689268 0.76 HDAC1 (0.44) HDAC1HDAC2HDAC3ALDH1A1LMNA
SCHEMBL14312607 0.76 HDAC1 (0.53) HDAC1HDAC2HDAC3MEN1KMT2A
SCHEMBL2107883 0.75 HDAC1 (0.62) HDAC1HDAC2HDAC3MEN1KMT2A
SCHEMBL2107532 0.75 HDAC1 (0.53) HDAC1HDAC2HDAC3MEN1KMT2A
SCHEMBL2686355 0.74 HDAC1 (0.54) HDAC1KMT2APOLBNPC1RAB9A
SCHEMBL4312019 0.74 HDAC1 (0.54) HDAC1HDAC2HDAC3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP claimed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US claimed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US claimed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP claimed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO claimed
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC2 42/4885HDAC3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.